Improved outcomes in metastatic colon cancer: Giving credit where credit is due
A partir d'une revue de la littérature publiée entre 1993 et 2015 (96 essais identifiés), cette étude analyse l'évolution de la survie globale associée aux nouveaux traitements des patients atteints d'un cancer colorectal métastatique
For decades, effective treatment for metastatic colorectal cancer (mCRC) was an almost impenetrable obstacle, with a single therapeutic option—fluorouracil. Outcomes were highly consistent across time and across trials, with a median overall survival (OS) of approximately 1 year. The last 20 years have seen highly clinically relevant improvements in not only OS but also progression-free survival (PFS) and response rates. In the most recently reported large first-line randomized trials, median OS has reached or exceeded 30 months.
JAMA Oncology , commentaire, 2014